动脉瘤性蛛网膜下腔出血患者应激相关性消化道出血:多中心回顾性观察研究
这项17中心回顾性观察研究纳入627例住院≥48小时且入院无活动性消化道出血的aSAH患者,评估应激相关性黏膜出血(SRMB)发生率、抑酸预防效果及危险因素。结果显示临床重要消化道出血发生率为4.9%,出血前接受抑酸药者出血风险显著低于未预防者(OR 0.39,95%CI 0.18-0.83)。多因素回归识别颅内压升高、肌酐清除率<60 ml/min、脑血管痉挛为SRMB危险因素,其中脑血管痉挛为既往未描述的新的危险因素(OR 2.5,95%CI 1.09-5.79)。
要点
- aSAH患者临床重要消化道出血发生率为4.9%,与一般重症人群相近。
- 出血前接受抑酸药预防者消化道出血风险显著降低(OR 0.39,95%CI 0.18-0.83)。
- 颅内压升高、肌酐清除率<60 ml/min、凝血功能障碍、机械通气>48小时及脑血管痉挛与消化道出血相关。
- 脑血管痉挛是新发现的消化道出血危险因素(OR 2.5,95%CI 1.09-5.79)。
- 61%的出血患者在出血前已接受药物预防,提示部分出血仍发生在预防背景下。
适用人群与场景
- 17个中心的动脉瘤性蛛网膜下腔出血(aSAH)住院患者,纳入住院时间≥48小时者。
- 排除入院时即有活动性消化道出血者及住院时间<48小时者。
- 数据收集范围为入院后前21天或至出院(以先到者为准)。
诊断标准与关键阈值
- 原文未提及明确的消化道出血诊断标准名称或具体界值。
- 主要结局为临床重要消化道出血(clinically important GI bleeding),原文未给出其具体定义。
- 肾功能异常定义为肌酐清除率<60 ml/min。
- prolonged mechanical ventilation 定义为>48小时。
处置流程与药物剂量
- 原文提及出血前接受酸抑制药物(acid suppressant agent)预防者出血风险较低(OR 0.39,95%CI 0.18-0.83),但未给出具体药物名称、剂量、给药途径及疗程。
- 原文未提及SRMB预防的启动或停止阈值。
红旗征与不能漏的情况
- 颅内压升高:与消化道出血风险相关,原文未给出具体处理措施。
- 脑血管痉挛:与消化道出血风险相关(OR 2.5,95%CI 1.09-5.79),原文未给出具体处理措施。
- 凝血功能障碍:与消化道出血风险相关,原文未给出具体处理措施。
- 肌酐清除率<60 ml/min:与消化道出血风险相关,原文未给出具体处理措施。
- 机械通气>48小时:与消化道出血风险相关,原文未给出具体处理措施。
研究设计与关键结果
- 研究类型:多中心(17中心)回顾性观察研究,每中心回顾最近最多50例aSAH病例。
- 样本量:共纳入627例患者。
- 主要结局:临床重要消化道出血总体发生率为4.9%。
- 出血患者中19例(61%)在出血前接受了药物预防,12例(39%)出血时未接受药物预防。
- 接受酸抑制药物者消化道出血风险低于未接受药物预防者(OR 0.39,95%CI 0.18-0.83)。
- 多因素回归识别颅内压升高、肌酐清除率<60 ml/min、脑血管痉挛为消化道出血危险因素;脑血管痉挛OR 2.5(95%CI 1.09-5.79)。
- 结论中列出的危险因素还包括 prolonged mechanical ventilation(>48小时)和凝血功能障碍。
证据类型、等级与局限
- 证据类型:多中心回顾性观察研究。
- 局限:回顾性设计、观察性研究,原文作者指出需进一步前瞻性研究确认该人群中的观察结果。
对床旁实践的改变
- 对aSAH患者可考虑评估消化道出血风险,尤其存在颅内压升高、肌酐清除率<60 ml/min、凝血功能障碍、机械通气>48小时或脑血管痉挛者。
- 酸抑制药物预防可能与较低的消化道出血风险相关,但原文未提供具体药物方案,不能据此制定剂量或疗程推荐。
- 原文未说明预防性抑酸是否应常规用于所有aSAH患者,临床决策需结合个体风险评估。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVE: Stress-related mucosal bleeding (SRMB) occurs in approximately 2-4% of critically ill patients. Patients with aneurysmal subarachnoid hemorrhage (aSAH) have a (diffuse) space-occupying lesion, are critically ill, often require mechanical ventilation, and frequently receive anticoagulation or antiplatelet therapy after aneurysm embolization, all of which may be risk factors for SRMB. However, no studies have evaluated SRMB in patients with aSAH. Aims of the study were to determine the incidence of SRMB in aSAH patients, evaluate the effect of acid suppression on SRMB, and identify specific risk factors for SRMB.
METHODS: This was a multicenter, retrospective, observational study conducted across 17 centers. Each center reviewed up to 50 of the most recent cases of aSAH. Patients with length of stay (LOS) < 48 h or active GI bleeding on admission were excluded. Variables related to demographics, aSAH severity, gastrointestinal (GI) bleeding, provision of SRMB prophylaxis, adverse events, intensive care unit (ICU), and hospital LOS were collected for the first 21 days of admission or until hospital discharge, whichever came first. Descriptive statistics were used to analyze the data. A multivariate logistic regression modeling was utilized to examine the relationship between specific risk factors and the incidence of clinically important GI bleeding in patients with aSAH.
RESULTS: A total of 627 patients were included. The overall incidence of clinically important GI bleeding was 4.9%. Of the patients with clinically important GI bleeding, 19 (61%) received pharmacologic prophylaxis prior to evidence of GI bleeding, while 12 (39%) were not on pharmacologic prophylaxis at the onset of GI bleeding. Patients who received an acid suppressant agent were less likely to experience GI bleeding than patients who did not receive pharmacologic prophylaxis prior to evidence of bleeding (OR 0.39, 95% CI 0.18-0.83). The multivariate regression analysis identified any instance of elevated intracranial pressure, creatinine clearance < 60 ml/min and the incidence of cerebral vasospasm as specific risk factors associated with GI bleeding. Cerebral vasospasm has not previously been described as a risk for GI bleeding (OR 2.5 95% CI 1.09-5.79).
CONCLUSIONS: Clinically important GI bleeding occurred in 4.9% of patients with aSAH, similar to the general critical care population. Risk factors associated with GI bleeding were prolonged mechanical ventilation (> 48 h), creatinine clearance < 60 ml/min, presence of coagulopathy, elevation of intracranial pressure, and cerebral vasospasm. Further prospective research is needed to confirm this observation within this patient population.
参考来源
- Ali D, Barra ME, Blunck J, et al. Stress-Related Gastrointestinal Bleeding in Patients with Aneurysmal Subarachnoid Hemorrhage: A Multicenter Retrospective Observational Study. Neurocrit Care. 2020. PMID: 33150575. doi:10.1007/s12028-020-01137-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。